In a phase I clinical trial, the combination of Capivasertib (an AKT inhibitor) and Olaparib (a PARP inhibitor) achieved clinical benefit (RECIST CR/PR or SD ≥ 4 months) in 11 out of 25 patients with advanced ovarian cancer [20]. This evidence concerns the gene PARP1 and ovarian cancer.